Key result
Elevated pulmonary artery systolic pressure is linked to ~134% higher MACE risk in LAAO patients.
Why the study?
Risk factors for adverse cardiovascular events in NVAF patients undergoing LAAO remain largely unknown, and whether elevated PASP is associated with postprocedure adverse events and MACE had not been determined.
Is elevated preprocedure pulmonary artery systolic pressure associated with increased risk of MACE and pericardial effusion in NVAF patients undergoing LAAO?
Population
530 consecutive NVAF patients at high risk of stroke or bleeding undergoing LAAO
Comparison
PASP ≥39.5 mmHg vs PASP <39.5 mmHg
Design
Retrospective cohort study
Follow-up
Median 12 months
Authors
Loading...
Elevated pre-LAAO PASP was associated with higher MACE risk; leaves open whether PASP-guided stratification improves outcomes in NVAF.
Cohort (n=530)
Is elevated preprocedure pulmonary artery systolic pressure associated with increased risk of MACE and pericardial effusion in NVAF patients undergoing LAAO?
Effect estimate: HR 2.337 (95% CI 1.207-4.526)
p-value: p=0.012
Elevated preprocedural pulmonary artery systolic pressure (≥39.5 mmHg) is a significant predictor of mid-term MACE and postprocedural pericardial effusion in patients undergoing LAAO.
Zou et al. (2021) conducted a cohort in Nonvalvular atrial fibrillation (n=530). Elevated pulmonary artery systolic pressure (PASP ≥39.5 mmHg) vs. PASP <39.5 mmHg was evaluated on Major adverse cardiovascular events (myocardial infarction, definite heart failure, stroke, or all-cause death) (HR 2.337, 95% CI 1.207-4.526, p=0.012). Elevated pulmonary artery systolic pressure (≥39.5 mmHg) significantly increased the risk of MACE in atrial fibrillation patients undergoing LAAO (HR 2.337; 95% CI 1.207-4.526; P=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: